The duration of the study for an individual patient will start from the signature of the main informed consent and include a screening period of up to 28 days, a treatment period [max 35 cycles or until PD], an end-of-treatment visit 30 days + 7 days following the last administration of study drug (or until the patient receives another anticancer therapy, whichever is earlier), and a follow-up visit 3 months after treatment discontinuation and every 3 months following, until disease progression, or initiation of another antitumor treatment, or final cohort cut-off, whichever is earlier
Primary Objective:~-To determine the antitumor activity of SAR444245 in combination with cemiplimab.~Secondary Objectives:~To determine the recommended phase 2 dose and to assess the safety profile of SAR444245 when combined with cemiplimab~To assess other indicators of antitumor activity~To assess the concentrations of SAR444245 when given in combination with cemiplimab~To assess the immunogenicity of SAR444245~To assess active concentrations of cemiplimab when given in combination with SAR444245